PBYI News and Press, Puma Biotechnology Inc From 12/11/19

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The p...

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

Before we ring in 2020, December will be ripe for swings in biotech stock prices. 2019 started strong, waned, and then regained momentum amid a slew of successful clinical trial results, several acquisition announcements, and positive drug approval decisions that came often months ahead of the U...

Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX® (neratinib) in Singapore from the Health Sciences Authority (HSA), a statutory board under the Minist...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Pierre Fabre have agreed to extend the terms of the license agreement in which Puma granted Pierre Fabre exclusive rights to develop and commercialize NERLYNX® (neratinib) within Europe and part of Africa. The amen...

Investors knew ahead of the Nov. 6 arrival of Puma Biotechnology 's (NASDAQ: PBYI)  third-quarter update that the report was going to be an important one. The question on everyone's mind was pretty straightforward: Had the company been able to do anything to address physicians' waning ent...

Party City Holdco (NYSE: PRTY ) -44%  after Q3 results . More news on: Party City Holdco Inc., EyePoint Pharmaceuticals, Inc., Fossil Group, Inc., Stocks on the move, Read more ...

Image source: The Motley Fool. Puma Biotechnology Inc   (NASDAQ: PBYI) Q3 2019 Earnings Call Nov 6, 2019 , 4:30 p.m. ET Operator Continue reading

Puma Biotechnology, Inc. (PBYI) Q3 2019 Earnings Conference Call November 6, 2019, 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Conference Call Participants Alethia Young - Cantor...